AU · rank #9 · 2026-09-08
ABVX
PARIS · EUR · $9.90B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.706 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.33 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $138.97 | +41.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +8.95% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | — |
| Gross margin TTM | +100.0% |
| 52w high | $139.00 |
| Market cap (USD) | $9.90B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Abivax SA is a clinical-stage biotechnology company developing obefazimod, a first-in-class oral miR-124 enhancer in Phase 3 development for moderate-to-severe ulcerative colitis and Crohn's disease.
Rationale
Positive global 44-week ABTECT maintenance data and a $920 million capital raise extending the cash runway to Q4 2027 support the 100% analyst revision agreement and 41.9% target upside signal.
Material risks
- 1FDA safety scrutiny or rejection of the planned late Q4 2026 NDA submission due to cancer cases observed at higher doses during late-stage trials.
- 2Extreme analyst target price dispersion of 79.2% across a very thin coverage base of only three analysts leaves the consensus upside signal highly sensitive to individual model changes.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.